Live Science's health channel editor makes predictions about the medical breakthroughs and public health shifts to come in ...

Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...

Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

Cardiovascular disease remains a leading global cause of death, and we break down its pathology, risk factors, and the ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

In 2026, Robert F. Kennedy Jr.'s health policy changes will start playing out on GLP-1s, dietary guidelines, and rural health ...

Based Detection, Linguistic Biomarkers, Machine Learning, Explainable AI, Cognitive Decline Monitoring Share and Cite: de Filippis, R. and Al Foysal, A. (2025) Early Alzheimer’s Disease Detection from ...

FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...

Complement receptor 1 had the highest predictive accuracy for adverse event outcomes in PBC and was better than traditional liver fibrosis markers, including the Fibrosis-4 index. The complement ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

Department of Rheumatology, Toronto University, Toronto, ON, Canada. Department of Rheumatology, Toronto University, Toronto, ON, Canada. Department of Internal ...

Novo Nordisk strikes another deal, this time with Omeros, amid a broader pipeline restructuring that recently claimed its cell therapy work. Novo Nordisk is plunking down as much as $2.1 billion to ...